Nature Medicine · 6 August 2026 · From issue 17
Psilocybin-assisted therapy for treatment-resistant major depressive disorder in a public healthcare setting: a randomized controlled trial
A single psilocybin dose cut depression scores far more than a placebo in hard to treat depression.
James J. Rucker, Tim Mantingh et al.
A single dose of the drug psilocybin, given with talk therapy support, lowered depression scores much more than a placebo in people whose depression had not improved with other treatments. Sixty people took part at one hospital in England. Almost everyone stayed in the study and finished all check-ins. The benefit showed up after three weeks and was still there at six weeks.
Integrity screen: passed (3 checks) Checked 20 September 2026. Read the source
The plain-language reading of this paper is in the full issue, for subscribers.
Read the full issue